Nova Leap HealthNVLPF 50 EBITDA Margin % is 8.69% as of Mar. 2026, which is 676% above its 10-year median of 1.12. GuruFocus rates NVLPF with a GF Score™ of 50/100 and a GF Value™ of $0.19 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Nova Leap Health ranks worse than 64.97% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nova Leap Health's EBITDA for the
three
months ended in Mar. 2026 was $0.68 Mil. Nova Leap Health's Revenue for the
three
months ended in Mar. 2026 was $7.85 Mil. Therefore, Nova Leap Health's EBITDA margin for the quarter that ended in Mar. 2026 was 8.69%.
Nova Leap Health (OTCPK:NVLPF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nova Leap Health EBITDA Margin % Related Terms
Nova Leap Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nova Leap Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NVLPF vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Nova Leap Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Leap Health EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nova Leap Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nova Leap Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Leap Health (NVLPF) has a EBITDA Margin % of 8.69% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nova Leap Health and its competitors. This is 676% above median its historical median of 1.12. According to the industry distribution chart, Nova Leap Health ranks #434 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 65%.
Is Nova Leap Health's EBITDA Margin % too high?
Nova Leap Health's current EBITDA Margin % of 8.69% is 676% above median its 10-year median of 1.12. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Nova Leap Health's value of 8.69% is 14.9% below this industry median. Based on the distribution chart, Nova Leap Health ranks #434 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Nova Leap Health has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nova Leap Health's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Nova Leap Health ranks #434 out of 668 companies for EBITDA Margin %. This places Nova Leap Health in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Nova Leap Health's value of 8.69% is 14.9% below this benchmark. While the company's 10-year median is 1.12 vs. the industry median of 10.21, Nova Leap Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nova Leap Health's current EBITDA Margin % of 8.69% is 14.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nova Leap Health and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Leap Health's current EBITDA Margin % is 8.69%, which is 676% above median its own 10-year median of 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Leap Health stock overvalued right now?
Based on GuruFocus' analysis, Nova Leap Health (NVLPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.19, compared to a current price of $0.25 — trading 29.7% above its estimated fair value. The current EBITDA Margin % is 8.69%, which is 676% above median its 10-year median of 1.12 and 14.9% below the Healthcare Providers & Services industry median of 10.21. Nova Leap Health's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nova Leap Health (NVLPF), the current EBITDA Margin % is 8.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Leap Health (NVLPF) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Leap Health stock appears to be overvalued.
The current stock price of $0.25 is trading 29.7% above its estimated GF Value™ of $0.19.
GuruFocus considers Nova Leap Health to be Modestly Overvalued.
Key valuation signals for NVLPF:
EBITDA Margin %: 8.69% (676% above median its 10-year median of 1.12)
GF Value™: $0.19 vs. price of $0.25 (29.7% above fair value)
Industry Position: 14.9% below the Healthcare Providers & Services median (#434 of 668)
No single metric tells the full story. See the NVLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Leap Health Corp operates in the healthcare industry. The company is a provider of home and home health care services to clients..The principal business activities of the company and its subsidiaries are to provide skilled and non-medical home care to clients. Its service offerings include meal preparation, housekeeping, transportation, personal care, and medication reminders. Its segments comprise Canadian and U.S. operations. The company derives a majority of its revenue from the United States.
50GF Score
Get the complete analysis for NVLPF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVLPF has been successfully added to your 
